Cetuximab + Paclitaxel

DRUG2 trials

Sponsors

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Conditions

Head and Neck CancerRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

TerminatedNCT03887442

Grupo Español de Tratamiento de Tumores de Cabeza y CuelloHead and Neck Cancer

Start: 2011-02-16End: 2012-10-02Updated: 2021-01-07

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

CompletedNCT04282109

Grupo Español de Tratamiento de Tumores de Cabeza y CuelloRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2020-06-03End: 2024-03-21Updated: 2025-06-26

Related Papers

Centrally determined PD-L1 among non-eligible for cisplatin-based chemotherapy recurrent/metastatic head and neck patients (R/M HNSCC pts): Pathology outcomes from the NIVOTAX trial.

Journal of Clinical Oncology2022-06-01

Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study.

Journal of Clinical Oncology2021-05-20